NCT06391593View on ClinicalTrials.gov

PD, PK, and Safety of ALTO-203 in Patients With MDD

PHASE2CompletedINTERVENTIONAL

Enrollment

69

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

April 14, 2025

Study Completion Date

April 21, 2025

Conditions

Major Depressive DisorderAnhedonia

Interventions

DRUG

ALTO-203 25 μg

Active, ALTO-203 25 μg

DRUG

ALTO-203 75 μg

Active, ALTO-203 75 μg

DRUG

Placebo

Comparator, Placebo-to-match

Trial Locations (15)

21208

Site 4054, Pikesville

30030

Site 4031, Atlanta

32801

Site 4005, Orlando

34711

Site 4059, Clermont

44145

Site 4075, Westlake

77081

Site 4072, Houston

78737

Site 4040, Austin

84015

Site 4007, Clinton

85704

Site 4058, Tucson

89121

Site 4036, Las Vegas

90504

Site 4023, Torrance

92056

Site 4082, Oceanside

98007

Site 4033, Bellevue

08053

Site 4022, Marlton

08540

Site 4134, Princeton

Sponsors

Lead Sponsor

Alto Neuroscience

All Listed Sponsors

lead

Alto Neuroscience

INDUSTRY